Thursday - May 22, 2025
Arbor Biotechnologies to Present Preclinical Data for ABO-101 in PH1 at the American Society of Gene and Cell Therapy 28th Annual Meeting
May 14, 2025
CAMBRIDGE, Massachusetts, May 14 -- Arbor Biotechnologies, a biotechnology company that says it discovers and develops genetic medicines, issued the following news release:

* * *

Arbor Biotechnologies to Present Preclinical Data for ABO-101 in PH1 at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

* Data from oral presentation supported ABO-101 IND and CTA approval for clinical assessment in primary hyperoxaluria type 1 (PH1) in th . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products